Mingyu Li

发表

A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results.

R. Stupp, W. Mason, S. Kesari, 2018 .

Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients

Anita Gandhi, Rajesh Chopra, Josep Tabernero, 2013, PloS one.

APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

J. Berlin, A. Biankin, P. Philip, 2019, Journal of Clinical Oncology.

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Joon-Oh Park, J. Berlin, A. Biankin, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.

Keith E. Volmar, M. Kriegsmann, W. Weichert, 2020, The Journal of clinical investigation.

Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer

E. Van Cutsem, J. Tabernero, S. Tejpar, 2013, PloS one.

APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).

A. Biankin, P. Philip, M. Tempero, 2016 .

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study

S. Verstovsek, T. Gerike, R. Mesa, 2019, Clinical Lymphoma Myeloma and Leukemia.

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

R. Xu, H. Pan, Yanqiao Zhang, 2017, BMC Cancer.

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

Jianming Xu, L. Shen, R. Xu, 2017, BMC Cancer.

First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).

M. Konopleva, A. Chanan-Khan, Dajun Yang, 2021 .

ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

R. Stupp, W. Mason, S. Kesari, 2018, Neuro-Oncology.

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

A. Hauschild, A. Testori, M. Del Vecchio, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.

S. Verstovsek, T. Gerike, R. Mesa, 2019, Journal of Clinical Oncology.

A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.

J. Reeves, A. Tolcher, Dajun Yang, 2023, Journal of Clinical Oncology.

Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS)

T. Kadia, Dajun Yang, Y. Zhai, 2022, Blood.